Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01820754 2021-02-26

TOP1201 IPI

Phase 2 Completed

24 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02716272 2021-02-10

MAPS2

Phase 2 Completed

125 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT03048474 2021-01-20

INITIATE

Phase 2 Completed

36 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03256136 2020-11-04

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Phase 2 Completed

9 enrolled 15 charts

Thoracic

Lung Neoplasms

NCT02221739 2020-05-11

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

39 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03823625 2020-03-25

SQUINT

Phase 2 Unknown

112 enrolled

Thoracic

Squamous-Cell Lung Cancer

NCT04250246 2020-01-31

NIBIT-ML1

Phase 2 Unknown

184 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03527251 2018-05-30

SEQUENCE

Phase 1 Unknown

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

RAD-IO

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

COSINR

ALCG-01

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

DREAM3R

FLINN

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ATLAS

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NA_00092076

DICIPLE

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

TOP1705

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

GALAXY 3

TOP2101

Osi+Ipi

NIVIPI-Brain

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

NIPU

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

ROME

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

eNERGY

Microbiome Immunotherapy Toxicity and Response Evaluation

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

LUNGVIR

Luscid

Neoadjuvant Immunotherapy in Brain Metastases

TOP1201 IPI

MAPS2

INITIATE

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

SQUINT

NIBIT-ML1

SEQUENCE